The platform is being introduced to expand access to treatments for people living with chronic conditions
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Wegovy achieved significant weight loss with one in three study participants losing 20% or more body weight
Pete Pharma will leverage FABRX’s extensive foundation of scientific validation to deliver a commercially viable, pharmacy-ready solution in the US
The FDA is beginning rulemaking to close the “adequate provision” loophole
WIDAPLIK is the first and only FDA-approved triple combination medication for use as an initial therapy in patients likely to need multiple drugs to achieve blood pressure goals
Attorney General Ken Paxton sued pharmaceutical giant Eli Lilly for bribing and illegally inducing medical providers to prescribe its most profitable drugs
Tamsulosin, an alpha-1 adrenergic receptor blocker, combined with Dutasteride, a dual 5- alpha-reductase inhibitor, is indicated for the treatment of moderate to severe symptoms of benign prostatic hyperplasia (BPH) in adult men
Vasograin Plus represents a major advancement in the treatment of migraine
Baxdrostat demonstrated a statistically significant and clinically meaningful reduction of systolic blood pressure compared with placebo
Subscribe To Our Newsletter & Stay Updated
